Haemochromatosis

Lancet

Volumn 370, Issue 9602, 2007, Pages 1855-1860

  Adams, Paul C ^a   Barton, James C ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b SOUTHERN IRON DISORDERS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE IDENTIFICATION; GENE MUTATION; GENETIC COUNSELING; HEMOCHROMATOSIS; HOMOZYGOTE; HUMAN; IRON OVERLOAD; LIVER CIRRHOSIS; LIVER FIBROSIS; MORTALITY; PHLEBOTOMY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SCREENING TEST;

EID: 36549053552     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61782-6     Document Type: Review

References (72)

1. Feder J., Gnirke A., Thomas W., et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 13 (1996) 399-408
2. Adams P. Hemochromatosis case definition-out of focus?. Nature Clin Pract Gastroenterol Hepatol 3 (2006) 178-179
3. Adams P., Reboussin D., Barton J., et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 352 (2005) 1769-1778
4. Gleeson F., Ryan E., Barrett S., and Crowe J. Clinical expression of haemochromatosis in Irish C282Y homozygotes identified through family screening. Eur J Gastroenterol Hepatol 16 (2004) 859-863
5. Distante S., Robson K., Graham-Campbell J., Arnaiz-Villena A., Brissot P., and Worwood M. The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet 115 (2004) 269-279
6. Merryweather-Clarke A., Pointon J., Jouanolle A., Rochette J., and Robson K. Geography of HFE C282Y and H63D mutations. Genet Test 4 (2000) 183-198
7. Ganz T., and Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol 290 (2006) G199-G203
8. Pietrangelo A. Hereditary hemochromatosis. Annu Rev Nutr 26 (2006) 251-270
9. Babitt J., Huang F., Wrighting D., et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38 (2006) 531-539
10. Truksa J., Peng H., Lee P., and Beutler E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci USA 103 (2006) 10289-10293
11. Wang R., Li C., Xu X., et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2 (2005) 399-409
12. Nemeth E., Tuttle M., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004) 2090-2093
13. Waheed A., Parkkila S., Zhou X., et al. Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA 94 (1997) 12384-12389
14. Pietrangelo A. Hereditary hemochromatosis: a new look at an old disease. N Engl J Med 350 (2004) 2383-2397
15. Bridle K., Frazer D., Wilkins S., et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homeostasis. Lancet 361 (2003) 661-673
16. De Domenico I., Ward D., Nemeth E., et al. The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci USA 102 (2005) 8955-8960
17. Papanikolaou G., Samuels M., Ludwig E., et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 36 (2004) 77-82
18. Merryweather-Clarke A., Cadet E., Bomford A., et al. Digenic inheritance of mutations in HAMP and HFE result in different types of hemochromatosis. Hum Mol Genet 12 (2003) 2241-2247
19. LeGac G., Scotet V., Ka C., et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifer of the C282Y homozygous phenotype. Hum Mol Genet 13 (2004) 1913-1918
20. Lee P., Barton J., Brandhagen D., and Beutler E. Hemojuvelin (HJV) mutations in persons of European, African-American and Asian ancestry with adult onset haemochromatosis. Br J Haematol 127 (2004) 224-229
21. Van Vlierberghe H., Langlois M., Delanghe J., et al. Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients. J Hepatol 35 (2001) 707-711
22. Carter K., Bowen D., McCune C., and Worwood M. Haptoglobin type neither influences iron accumulation in normal subjects nor predicts clinical presentation in HFE C282Y haemochromatosis: phenotype and genotype analysis. Br J Haematol 122 (2003) 326-332
23. Krayenbuehl P., Maly F., Hersberger M., et al. Tumor necrosis factor-α -308G>A allelic variant modulates iron accumulation in patients with hereditary hemochromatosis. Clin Chem 52 (2006) 1552-1558
24. Fargion S., Valenti L., Dongiovanni P., et al. Tumor necrosis factor α promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood 97 (2001) 3707-3712
25. Acton R., Snively B., Barton J., et al. A genome-wide scan suggests a region on chromosome 16p is a determinant of serum ferritin after adjusting for HFE. Clin Genet 71 (2007) 518-529
26. Adams P., Reboussin D., McLaren C., et al. Biological variability of transferrin saturation and unsaturated iron binding capacity. Am J Med 120 (2007) e1-e7
27. Adams P., Zaccaro D., Moses G., et al. Comparison of the unsaturated iron binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the HEIRS study. Clin Chem 51 (2005) 1048-1051
28. Delatycki M., Allen K., Nisselle A., et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 366 (2005) 316
29. Power T., and Adams P. Psychosocial impact of genetic screening for hemochromatosis in population screening and referred patients. Genet Test 5 (2001) 107-110
30. Patch C., Roderick P., and Rosenberg W. Comparison of genotypic and phenotypic strategies for population screening in hemochromatoisis: assessment of anxiety, depression and perception of health. Genet Med 7 (2005) 550-556
31. Hall M., McEwen J., Barton J., et al. Concerns in a primary care population about genetic discrimination by insurers. Genet Med 7 (2005) 311-316
32. Hall M., Barton J., Adams P., et al. Genetic screening for iron overload: no evidence of discrimination at 1 year. J fam Pract 56 (2007) 829-834
33. Anderson R., Press N., Tucker D., et al. Patient acceptability of genotypic testing for hemochromatosis in primary care. Genet Med 7 (2005) 557-563
34. Gandon Y., Guyader D., Heautot J., et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology 193 (1994) 533-538
35. St Pierre T., Clark P., Chua-anusorn W., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105 (2005) 855-861
36. Beaton M., Guyader D., Deugnier Y., Moirand R., Chakrabarti S., and Adams P. Non-invasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology 36 (2002) 673-678
37. Morrison E., Brandhagen D., Phatak P., et al. Serum ferritin levels predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 138 (2003) 627-633
38. Beutler E., Felitti V., Koziol J., Ho N., and Gelbart T. Penetrance of the 845G to A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359 (2002) 211-218
39. McLaren G., McLaren C., Adams P., et al. Symptoms and signs of hemochromatosis in HFE C282Y homozygotes identified by screening in primary care. Blood 108 (2006) 444a
40. Asberg A., Hveem K., Kruger O., and Bjerve K. Persons with screening-detected haemochromatosis: as healthy as the general population?. Scand J Gastroenterol 37 (2002) 719-724
41. McCune C., Ravine D., Carter K., et al. Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients. Gut 55 (2006) 554-562
42. Wojcik J., Speechley M., Kertesz A., Chakrabarti S., and Adams P. Natural history of C282Y homozygotes for haemochromatosis. Can J Gastroenterol 16 (2002) 297-302
43. Niederau C., Fischer R., Purschel A., Stremmel W., Haussinger D., and Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110 (1996) 1107-1119
44. Adams P. Hepatocellular carcinoma in hereditary hemochromatosis. Can J Gastroenterol 7 (1993) 37-41
45. Beaton M., and Adams P. Prognostic factors and survival in patients with hereditary hemochromatosis. Can J Gastroenterol 20 (2006) 257-260
46. Fletcher L., Dixon J., Purdie D., Powell L., and Crawford D. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 122 (2002) 563-565
47. Adams P., and Agnew S. Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings. Hepatology 23 (1996) 724-727
48. Acton R., Barton J., Passmore L., et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care 29 (2006) 2084-2089
49. Hramiak I., Finegood D., and Adams P. Factors affecting glucose tolerance in hereditary hemochromatosis. Clin Invest Med 20 (1997) 110-118
50. McClain D., Abraham D., Rogers J., et al. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia 49 (2006) 1661-1669
51. Andersen R., Tybjaerg-Hansen A., Appleyard M., Birgens H., and Nordestgaard B. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 103 (2004) 2914-2919
52. Yamashita C., and Adams P. Natural history of the C282Y homozygote of the hemochromatosis gene (HFE) with a normal serum ferritin level. Clin Gastroenterol Hepatol 1 (2003) 388-391
53. Barton J., McDonnell S., Adams P., et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 129 (1998) 932-939
54. Beutler E. Natural history of hemochromatosis. Mayo Clin Proc 79 (2004) 305-306
55. Adams P., Kertesz A., and Valberg L. Rate of iron reaccumulation following iron depletion in hereditary hemochromatosis. Implications for venesection therapy. J Clin Gastroenterol 16 (1993) 207-210
56. Adams P., Frei J., Bradley C., and Lam D. Hepatic iron and iron absorption in hemochromatosis. Clin Invest Med 13 (1990) 256-258
57. Goodnough L., Price T., and Rudnick S. Iron-restricted erythropoiesis as a limitation to autologous blood donation in the erythropoietin-stimulated bone marrow. J Lab Clin Med 118 (1991) 289-296
58. Garry P., Koehler K., and Simon T. Iron stores and iron absorption: effects of repeated blood donations. Am J Clin Nutr 62 (2005) 611-620
59. Falize L., Guillygomarch A., Perrin M., et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 44 (2006) 472-477
60. Powell L., Dixon J., Ramm G., et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 166 (2006) 294-301
61. Hicken B., Tucker D., and Barton J. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol 98 (2003) 2072-2077
62. Barton J. Chelation therapy of iron overload. Curr Gastroenterol Rep 9 (2007) 74-82
63. Foucher J., Chanteloup E., Vergniol J., et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55 (2006) 403-408
64. Kowdley K., Brandhagen D., Gish R., et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 129 (2005) 494-503
65. Jackson H., Carter K., Darke C., et al. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol 114 (2001) 474-484
66. Rasmussen M., Folsom A., Catellier D., Tsai M., Garg U., and Eckfeldt J. A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 154 (2001) 739-746
67. Adams P. Population screening for hemochromatosis. Hepatology 29 (1999) 1324-1327
68. Adams P., and Valberg L. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterology 94 (1999) 1593-1600
69. Gagne G., Reinharz D., Laflamme N., Adams P., and Rousseau F. Hereditary hemochromatosis: effect of mutation penetrance and prevalence on cost-effectiveness of screening modalities. Clin Genet 71 (2007) 46-58
70. Whitlock E., Garlitz B., Harris E., Bell T., and Smith P. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventative Services Task Force. Ann Intern Med 145 (2006) 209-223
71. Delatycki M., Allen K., and Williamson R. Insurance agreement to facilitate genetic testing. Lancet 359 (2002) 1433
72. Adams P. Screening for haemochromatosis-producing or preventing illness?. Lancet 366 (2005) 269-271